This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

CardioNet, Inc. Reports Fourth Quarter And Full Year 2010 Financial Results

“Looking ahead to 2011, while some uncertainty has been removed with the national reimbursement rate, we will not be providing financial guidance until we reach a period of greater predictability. Our objective for 2011 is to organically grow patient volume in our core cardiac monitoring business through the disciplined execution of our sales plan. Additionally, we will continue to evaluate external opportunities that will augment this growth or provide complementary products and services. We will execute the full commercial launch of our next generation MCOT TM system, C5, which has enhanced features and a lower cost of sales. With $45 million of cash and investments and a strong operational foundation, I am confident we will execute on this plan.”

Fourth Quarter Financial Results

Revenues for the fourth quarter 2010 were $28.7 million, a decrease of 13.9% compared to $33.3 million in the fourth quarter 2009. The decrease in revenues was driven by lower volume as well as a reduction in non-contracted reimbursement. For the three months ended December 31, 2010, payor revenue was comprised of 36% Medicare and 64% commercial, and patient volume was comprised of 45% Medicare and 55% commercial.

Gross profit for the fourth quarter 2010 decreased to $16.7 million, or 58.3% of revenues, compared to $20.3 million, or 60.9% of revenues, in the fourth quarter 2009. Fourth quarter 2010 gross profit margin was impacted by the non-contracted reductions, as well as the lower MCOT TM patient volume.

On a GAAP basis, operating expenses for the fourth quarter 2010 were $21.3 million, a decrease of 40.5% compared to $35.8 million in the fourth quarter 2009. Operating expenses on an adjusted basis declined by 23.1% compared to the prior year quarter, excluding $1.6 million in the fourth quarter 2010 and $10.1 million in the fourth quarter 2009 related to restructuring and other nonrecurring charges. The decrease in operating expenses was driven by the Company’s cost reduction initiatives in response to the 2009 Medicare rate reduction.

2 of 7

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,351.38 +293.03 1.82%
S&P 500 1,948.86 +35.01 1.83%
NASDAQ 4,749.9790 +113.8740 2.46%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs